Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Buy
82
CIVB Quote, Financials, Valuation and Earnings
Last price:
$23.50
Seasonality move
:
-0.07%
Day range:
$22.98 - $23.75
52-week range:
$13.60 - $23.90
Dividend yield:
2.79%
P/E ratio:
10.41x
P/S ratio:
2.35x
P/B ratio:
0.92x
Volume:
28.1K
Avg. volume:
40.8K
1-year change:
56.8%
Market cap:
$366.7M
Revenue:
$151.9M
EPS (TTM):
$2.27
Analysts' Opinion
-
Consensus RatingCivista Bancshares has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.67, Civista Bancshares has an estimated upside of 8.62% from its current price of $23.63.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $24.00 representing 100% downside risk from its current price of $23.63.
Fair Value
-
According to the consensus of 5 analysts, Civista Bancshares has 8.62% upside to fair value with a price target of $25.67 per share.
CIVB vs. S&P 500
-
Over the past 5 trading days, Civista Bancshares has overperformed the S&P 500 by 0.9% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Civista Bancshares does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Civista Bancshares has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Civista Bancshares reported revenues of $40.1M.
Earnings Growth
-
Civista Bancshares has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Civista Bancshares reported earnings per share of $0.66.
Enterprise value:
477.3M
EV / Invested capital:
0.55x
Price / LTM sales:
2.35x
EV / EBIT:
3.66x
EV / Revenue:
3.07x
PEG ratio (5yr expected):
--
EV / Free cash flow:
10.18x
Price / Operating cash flow:
7.81x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
0.88%
Net Income Margin (TTM):
22.79%
Return On Equity:
9.22%
Return On Invested Capital:
4.09%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $150.1M | $153.2M | $155.7M | $36M | $40.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $2.84 | $2.33 | $2.27 | $0.41 | $0.66 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $809.8M | $980.6M | $743.3M | $742.5M | $421.2M | |
| Total Assets | $3.1B | $3.2B | $3.6B | $3.9B | $4.1B | |
| Current Liabilities | $29.5M | $23.9M | $233.4M | $368.5M | $360M | |
| Total Liabilities | $2.7B | $2.9B | $3.2B | $3.5B | $3.7B | |
| Total Equity | $350.1M | $327.7M | $347.7M | $369.7M | $397.4M | |
| Total Debt | $154.4M | $178.7M | $333.1M | $482.8M | $471.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $35.9M | $43.7M | $51.1M | $752K | $3.6M | |
| Cash From Investing | -$398.1M | -$307.3M | -$245.9M | -$34.2M | -$21.2M | |
| Cash From Financing | $2.3M | $261.3M | $234.9M | $23.3M | $44.9M | |
| Free Cash Flow | $28.2M | $41.3M | $46.9M | $629K | $3.5M | |
CIVB
Sector
Market Cap
$366.7M
$628.1M
Price % of 52-Week High
98.87%
87.3%
Dividend Yield
2.79%
1.97%
Shareholder Yield
2.24%
4.02%
1-Year Price Total Return
56.8%
9.14%
Beta (5-Year)
0.695
0.587
Dividend yield:
2.79%
Annualized payout:
$0.64
Payout ratio:
28.7%
Growth streak:
13 years
Technicals
8-day SMA
Buy
Level
$23.21
200-day SMA
Buy
Level
$19.86
Bollinger Bands (100)
Buy
Level
19.5 - 22.02
Chaikin Money Flow
Buy
Level
2.9M
20-day SMA
Buy
Level
$22.47
Relative Strength Index (RSI14)
Buy
Level
65.82
ADX Line
Buy
Level
22.02
Williams %R
Sell
Level
-11.6379
50-day SMA
Buy
Level
$20.63
MACD (12, 26)
Buy
Level
0.85
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
5.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.278)
Sell
CA Score
(Annual)
Level (-2.1646)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (2.7215)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
Stock Forecast FAQ
In the current month, CIVB has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CIVB average analyst price target in the past 3 months is $25.67.
-
Where Will Civista Bancshares Stock Be In 1 Year?
According to analysts, the consensus estimate is that Civista Bancshares share price will rise to $25.67 per share over the next 12 months.
-
What Do Analysts Say About Civista Bancshares?
Analysts are divided on their view about Civista Bancshares share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Civista Bancshares is a Sell and believe this share price will drop from its current level to $24.00.
-
What Is Civista Bancshares's Price Target?
The price target for Civista Bancshares over the next 1-year time period is forecast to be $25.67 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CIVB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Civista Bancshares is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CIVB?
You can purchase shares of Civista Bancshares via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Civista Bancshares shares.
-
What Is The Civista Bancshares Share Price Today?
Civista Bancshares was last trading at $23.50 per share. This represents the most recent stock quote for Civista Bancshares. Yesterday, Civista Bancshares closed at $23.63 per share.
-
How To Buy Civista Bancshares Stock Online?
In order to purchase Civista Bancshares stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
99
SOC alert for May 20
Sable Offshore [SOC] is down 0.79% over the past day.
Buy
52
RGC alert for May 20
Regencell Bioscience Holdings [RGC] is up 31.16% over the past day.
Sell
40
GWLIF alert for May 20
Great-West Lifeco [GWLIF] is up 13.42% over the past day.
